close

EpiCept Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceutical products for the treatment of cancer and pain in the United States and Germany. The company's lead oncology product candidate is Ceplene, which is used for the treatment of acute myeloid leukemia. Its cancer product portfolio includes Azixa, a Phase II clinical trial product to treat the patients with primary glioblastoma and melanoma that has metastasized to the brain and non-small-cell lung cancer that has spread to the brain; and Crinobulin (EPC2407), a Phase I clinical trial completed oncology product candidate for the treatment of patients with advanced solid tumors and lymphomas. The company's pain product portfolio comprises EpiCept NP-1, a Phase II clinical trial product, which is a prescription topical analgesic cream for the relief of peripheral neuropathies; LidoPAIN BP, a prescription analgesic non-sterile patch to provide sustained topical delivery of lidocaine for the treatment of acute or recurrent lower back pain; EpiCept MP/DP, a spray gel matrix of morphine and lidocaine for the treatment of oral mucositis and dental pain; LidoPAIN TV, a topical lidocaine patch applied to the periauricular skin region (behind the ear) for the treatment of tinnitus; and LidoPAIN HM, a topical lidocaine patch applied to the forehead for the treatment of headaches. It principally has strategic alliances with Myriad Genetics, Inc. and DURECT Corporation. The company was founded in 1993 and is based in Tarrytown, New York.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	0.41
Volume	0
Volume Avg	36362
52 Week High	1.09
52 Week Low	0.29
PE	N/A
PE (group average)	39
EPS Year	0.00
EPS change Q/Q	-33.33%
EPS change Q/Q Yr ago	-60%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-81.48%
REV change Q/Q	-33.33%
REV change Q/Q Yr ago	0%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%